The Market’s Roaring Start: What’s Really Driving Stocks to Record Highs in 2026
The S&P 500 opened 2026 at a record and small caps led. What is behind the rotation, and which parts of the move rest on 15% earnings growth.
Beyond the Hype: 4 Unexpected Truths About Enterprise AI from Accenture’s Q1 2026 Earnings
Accenture’s quarter shows enterprise AI stalls on process debt and data debt. Four truths about what has to be fixed before AI scales.
Dr. Ed Yardeni’s 2026 Outlook: Why the ‘Roaring 2020s’ Demand a Portfolio Rotation
Ed Yardeni sees the S&P 500 at 7,700 by the end of 2026 and is ending a 15-year tech overweight. What that rotation would mean for a portfolio.
Why Great Leaders Treat Your Money Like It’s Their Own: The Capital Allocation Playbook
Nearly 80% of executives would trade long-term value for a quarterly number. How to spot the leaders who allocate capital like owners instead.
Weekly Market & ValueAligned Portfolio Review – November 28, 2025
The S&P 500 gained 3.7% during Thanksgiving week, marking its best holiday performance since 2008 ( Seeking Alpha). Small caps led the rally, with the Russell 2000 climbing 5.6% as rate-cut expectations surged ( Investing.com). J.P. Morgan now expects a 25-basis-point Fed rate cut in December, with futures pricing an 85% probability ( Bloomberg). Broadcom […]
ALERT: NVIDIA Corporation (NVDA) – Q3 Fiscal Year 2026 Earnings Review
NVIDIA posted record revenue of $57.0 billion, up 62%, with data center at $51.2 billion. What the quarter says about AI infrastructure demand.
Why Michael Burry’s Big Tech Warning is Irrelevant to Value Investors Using Residual Cash Earnings
Big Tech stretched server depreciation from three years to as long as ten, lifting reported earnings. Residual Cash Earnings sidesteps the whole argument.
Weekly Market Review 11.4.2025 End: Tech Pullback, Shutdown Woes, and VAP Outperformance
Week ended November 7, 2025. The S&P 500 fell 1.63% and the Nasdaq 100 dropped 4.04% on AI valuation worry, the shutdown, and a softer labor market.
The GLP-1 Revolution: How The Trump’s Pricing Deal Impacts Eli Lilly, Novo Nordisk, and Beyond
The November 2025 GLP-1 pricing deal cut list prices by up to 85%. What it does to Eli Lilly and Novo Nordisk economics, and to patient access.
Why Residual Cash Earnings (RCE) Is the Only Metric That Matters
Residual Cash Earnings captures growth, margin, and asset use in one number, and it does not care how a company sets its depreciation schedule.
